MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2011 » 1 » | Archive » Medical field » Fields » Psychiatry » Archive » Medical field » Sponsored articles »

Post-authorization Safety and Efficacy Study of Olanzapine (Zolrix®) in the Treatment of Schizophrenia and Bipolar Mania

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseases. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enables effective treatment at reduced strength and frequency of adverse reactions. We conducted a post-authorisation study in which 163 patients with schizophrenia and bipolar mania received olanzapine in the form of regular and orodispersible tablets (Zolrix®/Zolrix® orodispersible tablets, Krka, d.d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduced symptom expression in 79% of patients. Due to improvement in symptoms 41% of patients became only margi nally ill or even symptom-free. Olanzapine was very well tolerated by patients. Only in 25.2% of patients
medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number fell to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapine.

Authors:
Bon Jurij, Barbič - Žagar Breda, Bevec Matevž

Keywords:
schizophrenia, bipolar mania, efficacy, safety, orodispersible tablets, olanzapine

Cite as:
Med Razgl. 2011; 50: 97–9.

Download PDF >>
© 2022 Društvo Medicinski razgledi | Na vrh strani / To top ↑